Himadri Speciality Chemical approves ₹370 Cr capex for capacity expansion and new product lines
Himadri Speciality Chemical approved capex of ₹128 Cr for Anthraquinone/Carbazole capacity expansion, ₹70 Cr for India's first CNT manufacturing facility, and ₹170 Cr for Super Speciality Carbon Black. These expansions are expected to be commissioned between Q2FY27 and Q4FY28.
The substantial capex across multiple product lines, including setting up India's first CNT manufacturing facility, is expected to have a significant long-term impact on the company's revenue, profitability, and market leadership.
The company announced significant capital expenditure for capacity expansion and new product development, indicating a positive outlook for future growth and market positioning.
Himadri Speciality Chemical Ltd. announced the outcome of its Board Meeting held on July 15, 2026. The Board approved significant capital expenditure (capex) plans, including ₹128 Crores to expand the capacity for manufacturing Anthraquinone and Carbazole from 2600 MTPA to 5300 MTPA. This expansion will be implemented in two phases, with Phase 1 (2600 MTPA) expected by Q2FY27 and Phase 2 (2700 MTPA) by Q2FY28.
Additionally, the company approved a ₹70 Crores capex for setting up India's first manufacturing facility for Carbon Nano Tubes (CNT) with in-house developed technology. This facility, with an annual capacity of 200 MT, is slated for commissioning by Q4FY27 and aims to reduce import dependency.
The Board also sanctioned a ₹170 Crores capex for manufacturing Super Speciality Carbon Black (SSCB) with a production capacity of 6,000 MTPA, expected to be commissioned by Q4FY28. This move will enable the production of high-value carbon black for niche applications.
The company also reported its Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. The Board meeting commenced at 11:30 a.m. (IST) and concluded at 3:25 p.m. (IST).
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.